{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:09:45Z","timestamp":1788404985314,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc."},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,10,20]]},"abstract":"<jats:p>Omadacycline is a once-daily oral or intravenous (i.v.) aminomethylcycline antibiotic approved in the United States for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. Omadacycline pharmacokinetics were characterized in 18 patients with hepatic impairment and 12 matched healthy subjects. Patients with hepatic impairment received i.v. omadacycline at 100\u2009mg (mild hepatic impairment) or 50\u2009mg (moderate and severe hepatic impairment) and oral omadacycline at 300\u2009mg (mild hepatic impairment) or 150\u2009mg (moderate hepatic impairment); oral omadacycline was not evaluated in those with severe hepatic impairment.<\/jats:p>","DOI":"10.1128\/aac.01650-20","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:01:51Z","timestamp":1597928511000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline"],"prefix":"10.1128","volume":"64","author":[{"given":"Steven J.","family":"Kovacs","sequence":"first","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Ting","sequence":"additional","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangadhar","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Sun","sequence":"additional","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Novartis Institute for BioMedical Research, Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ken","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Villano","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010363477"},{"key":"e_1_3_2_3_2","unstructured":"Nabriva Therapeutics USA Inc. 2019. Xenleta (lefamulin injection and tablets) prescribing information. Revised August 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211672s000 211673s000lbl.pdf. Accessed 3 April 2020."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00176-15"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg248"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03431-14"},{"key":"e_1_3_2_7_2","volume-title":"Guidance for industry: pharmacokinetics in patients with impaired liver function: study design, data analysis, and impact on dosing and labeling","author":"Food and Drug Administration","year":"2003","unstructured":"Food and Drug Administration. 2003. Guidance for industry: pharmacokinetics in patients with impaired liver function: study design, data analysis, and impact on dosing and labeling. Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_8_2","unstructured":"Paratek Pharmaceuticals Inc. 2019. Nuzyra (omadacycline) prescribing information. Revised June 2019. https:\/\/www.nuzyra.com\/nuzyra-pi.pdf. Accessed 13 January 2020."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01393-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-16"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1213465"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02340.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847080-00003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz309"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00320-16"},{"key":"e_1_3_2_23_2","unstructured":"Warner Chilcott. 2008. Doryx (doxycycline delayed-release tablets) prescribing information. Revised June 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050795s005lbl.pdf. Accessed 14 February 2020."},{"key":"e_1_3_2_24_2","unstructured":"Medicis Pharmaceutical Corporation. 2019. Solodyn (minocycline extended release tablets) prescribing information. Revised March 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050808s014lbl.pdf. Accessed 14 February 2020."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_26_2","unstructured":"World Health Organization. 1991. WHO model prescribing information: drugs used in mycobacterial diseases. WHO Geneva Switzerland. https:\/\/apps.who.int\/iris\/handle\/10665\/37585."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr159"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz398"}],"updated-by":[{"DOI":"10.1128\/aac.02426-20","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01650-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01650-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:34:32Z","timestamp":1645479272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01650-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10,20]]}},"alternative-id":["10.1128\/AAC.01650-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01650-20","relation":{"correction":[{"id-type":"doi","id":"10.1128\/AAC.02426-20","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"2020-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01650-20"}}